Martina Rauner, WCO IOF-ESCEO 2022: Advances in Osteoimmunology
We caught up with Dr. Martina Rauner (Dresden University of Technology, Dresden, Germany) to learn more around the association between the skeletal and immune systems and the therapeutic opportunities arising from this.
‘Cross-talking between the immune system and the skeleton‘ was presented at WCO IOF-ESCEO 2022, 24-26 March, 2022
- What is known about the association between the skeletal and immune systems? (0:16)
- What molecules mediate the communication between the skeleton and the immune system? (0:48)
- What immune cells are involved in the cross-talk between the skeleton and the immune system? (1:42)
- What therapeutic opportunities have arisen as a result of our growing understanding of osteoimmunology? (2:36)
- How do you expect this field to develop in the coming years? (3:32)
Disclosures: Martina Rauner discloses receiving honoraria from Amgen, UCB, Vifor and Diasorin.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the WCO IOF-ESCEO annual meeting 2022.
Share this Video
Related Videos In Rheumatic Diseases
Machine-learning models as predictors of fractures in osteoporosis: Giovanni Adami, WCO-IOF-ESCEO 2023
In this study a machine-learning approach was investigated over two years to determine the efficacy of fracture risk prediction in osteoporosis. touchIMMUNOLOGY were delighted to speak with Dr. Giovanni Adami (University of Verona, Verona, Italy) to discuss the machine-learning models already available for screening osteoporosis and their limitations, the risk factors used as predictors of […]
Patrick Durez, ACR 2022: Factors associated with disease flare following COVID vaccination in inflammatory rheumatic and musculoskeletal diseases
The EULAR Coronavirus Vaccine (COVAX) physician-reported registry registered patients with pre-existing rheumatic and musculoskeletal diseases, who have been vaccinated against COVID-19. touchIMMUNOLOGY were delighted to speak with Prof Patrick Durez (Cliniques Universitaires Saint-Luc – Université Catholique de Louvain (UCL), Brussels, Belgium) to discuss the aims, methodology and findings of this study looking at factors associated […]
Robert Spiera, ACR 2022: Sarilumab for glucocorticoid resistant polymyalgia rheumatica – the SAPHYR study
The SAPHYR study (NCT03600818) investigated sarilumab, a fully human anti–IL-6Rα monoclonal antibody, in patients with glucocorticoid resistant polymyalgia rheumatica (PMR), measuring efficacy by sustained remission in PMR. touchIMMUNOLOGY were delighted to speak with Dr. Robert Spiera (Weill Cornell Medical College, New York, NY, USA) around the aims, design, inclusion criteria and findings from the SAPHYR […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!